PathoQuest
Paris
About PathoQuest
PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection. The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers. PathoQuest’s proprietary sample preparation, and its comprehensive database of pathogens genomic information, enables clinicians and biopharma companies to overcome the current limitation of infectious agent detection. PathoQuest’s Viral Safety testing service, directed towards biopharmaceutical companies, is the company’s first commercial application of its testing approach and has quickly established a revenue stream for the company from several major biopharma companies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $41.0M
- Funding stage: M&A
- Last round: Series B (Nov 2021)
- Website: pathoquest.com
- Phone: +33 170 821 790
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pathoquest-119305 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.